Literature DB >> 28626729

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

Masatoshi Kudo.   

Abstract

Entities:  

Year:  2017        PMID： 28626729      PMCID： PMC5473064          DOI： 10.1159/000462153

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  23 in total

Review 1.  Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Masumi Kadoya; Takuji Okusaka; Shiro Miyayama; Koichiro Yamakado; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami
Journal:  Oncology       Date:  2014-11-22       Impact factor: 2.935

Review 2.  Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).

Authors:  Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida
Journal:  Dig Dis       Date:  2015-10-21       Impact factor: 2.404

3.  Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

4.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

5.  Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.

Authors:  Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Oncology       Date:  2014-11-22       Impact factor: 2.935

6.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

7.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Authors:  Andrew X Zhu; Masatoshi Kudo; Eric Assenat; Stéphane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T P Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B Sellami; Li-Tzong Chen
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

8.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

10.  Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Fumihiko Kanai; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  Oncology       Date:  2014-09-06       Impact factor: 2.935
View more
  21 in total

1.  Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-04-17       Impact factor: 11.740

2.  Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-24       Impact factor: 11.740

Review 3.  Therapy in Advanced Hepatocellular Carcinoma.

Authors:  Hanna Javan; Farshid Dayyani; Nadine Abi-Jaoudeh
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

4.  Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Susumu Eguchi; Tatsuya Yamashita; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-02-18       Impact factor: 11.740

Review 5.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

6.  Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonio Daniele Pinna; Benjamin Djulbegovic; Federico Mazzotti; Luigi Bolondi
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740

7.  Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.

Authors:  Clarence Yen; Rohini Sharma; Lorenza Rimassa; Tadaaki Arizumi; Dominik Bettinger; Huay Yee Choo; Tiziana Pressiani; Michela E Burlone; Mario Pirisi; Laura Giordano; Anisa Abdulrahman; Masatoshi Kudo; Robert Thimme; Joong Won Park; David James Pinato
Journal:  Liver Cancer       Date:  2017-09-16       Impact factor: 11.740

Review 8.  Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Authors:  Fabio Piscaglia; Sadahisa Ogasawara
Journal:  Liver Cancer       Date:  2018-01-12       Impact factor: 11.740

9.  Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.

Authors:  Hongzhi Wang; Satheesh Ellipilli; Wen-Jui Lee; Xin Li; Mario Vieweger; Yuan-Soon Ho; Peixuan Guo
Journal:  J Control Release       Date:  2020-12-13       Impact factor: 9.776

10.  Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.

Authors:  Lu Cao; Prashanth Prithviraj; Ritu Shrestha; Revati Sharma; Matthew Anaka; Kim R Bridle; George Kannourakis; Darrell H G Crawford; Aparna Jayachandran
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.